ALK
7 drugsAnaplastic Lymphoma Kinase
Predictive biomarker for patient selection in 5 indications
Understanding ALK
What it means: ALK rearrangements create fusion proteins that drive cancer growth. Most common is EML4-ALK fusion in lung cancer.
Why it matters: ALK+ cancers respond to ALK inhibitors: crizotinib, alectinib, brigatinib, lorlatinib. Often occurs in younger, non-smokers.
Testing: Tested via FISH, IHC, or NGS. FISH is the gold standard; NGS can identify specific fusion partners.
7
Approved Drugs
5
Indications
6
Companies
Search ALK Clinical Trials
Search recruiting trials on ClinicalTrials.gov